Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell…
Novartis has announced today that results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended…
Pfizer said on Thursday it would sell its global infusion therapy business, part of its $15 billion (11.8 billion pounds) Hospira acquisition last year, to ICU Medical Inc for $1 billion in cash and stock.
AstraZeneca’s heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, dealing a blow to a medicine that the company has tipped as a potential $3.5 billion-a-year seller by 2023.
Pfizer, which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
Horizon Pharma and Raptor Pharmaceutical Corp.have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued…
Verona Pharma #VRP appoints Vikas Sinha to the Board as a Non-Executive Director
The study, which will be conducted in up to 70 healthy individuals, aims to evaluate the tolerability of KarXT compared to xanomeline alone.